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Abstract
Purpose To characterize the pharmacokinetics (PK) of pertuzumab and trastuzumab in patients with HER2-positive meta-
static gastric or gastroesophageal junction cancer in the randomized, double-blind, phase III JACOB study (NCT01774786), 
and to evaluate the appropriateness of the pertuzumab regimen in these patients.
Methods Patients received 840 mg intravenous pertuzumab or placebo plus trastuzumab q3w and chemotherapy. Pertuzumab 
and trastuzumab were administered until disease progression or unacceptable toxicity. Chemotherapy was administered 
for up to six cycles or disease progression or unacceptable toxicity. Serum concentrations of pertuzumab and trastuzumab 
were measured. Pertuzumab PK was characterized across treatment cycles. The impact of anti-drug antibodies (ADAs) on 
pertuzumab PK and the impact of pertuzumab on trastuzumab PK were assessed. An exploratory exposure–efficacy analysis 
was also conducted.
Results In total, 374 patients in the pertuzumab arm had evaluable PK data. The mean observed pertuzumab steady-state 
serum trough (minimum) concentration (Cmin,ss) ± standard deviation was 114 ± 51.8 μg/mL. The target pertuzumab Cmin,ss 
of ≥ 20 μg/mL was reached in 99.3% of patients at Cycle 5 (steady state) and beyond. Greater than 90% of patients were 
above the PK target right after the first pertuzumab dose. There was no apparent impact of ADAs on pertuzumab PK nor of 
pertuzumab on trastuzumab PK. There were no differences in overall survival across Cycle 1 pertuzumab (Cmin) or Cycle 5 
pertuzumab (Cmin,ss) exposure quartiles.
Conclusions Pertuzumab exposure in JACOB was consistent with prior studies in advanced gastric cancer and breast cancer. 
The 840 mg q3w dose allowed the majority of patients in JACOB to achieve target pertuzumab concentrations and appears 
to be an appropriate dose selection.
Keywords Pertuzumab · Trastuzumab · Pharmacokinetics · HER2-positive · Metastatic gastroesophageal junction · 
Metastatic gastric cancer
Introduction
Pertuzumab  (PERJETA®, F. Hoffmann-La Roche Ltd, 
Basel, Switzerland) is a monoclonal antibody (mAb) that 
inhibits human epidermal growth factor receptor 2 (HER2) 
dimerization with other HER family receptors, thereby 
inhibiting mitogen-activated protein kinase and phospho-
inositide 3-kinase signaling pathways and promoting cell-
growth arrest and apoptosis [1, 2].
Adding pertuzumab to trastuzumab  (Herceptin®, F. 
Hoffmann-La Roche Ltd) may provide a more compre-
hensive HER2 pathway blockade (vs. trastuzumab alone) 
due to the complementary modes of action of the two 
drugs [3]. The addition of pertuzumab to trastuzumab has 
been shown to improve survival outcomes in patients with 
HER2-positive early breast cancer (EBC) and metastatic 
breast cancer (MBC) [4–6]. Although there are differences 
in tumor biology between HER2-positive breast cancer 
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and HER2-positive gastric cancer (GC), it was hypoth-
esized that the dual HER2-targeted regimen could also 
improve survival outcomes in patients with HER2-positive 
advanced GC (AGC) [7].
The pharmacokinetics (PK) and safety of pertuzumab 
plus trastuzumab and chemotherapy in patients with 
HER2-positive AGC was initially evaluated in the phase 
IIa dose-finding JOSHUA study (NCT01461057) [7]. This 
study showed that the combination of pertuzumab, tras-
tuzumab, and chemotherapy was well tolerated in these 
patients, with an adverse event (AE) profile similar to that 
seen in the ToGA trial (trastuzumab and chemotherapy vs. 
chemotherapy alone; NCT01041404) [8]. The PK analysis 
of JOSHUA found that mean serum trough levels at day 
43 were 37% lower in patients with HER2-positive AGC, 
compared with patients with HER2-positive MBC when 
the same dose was administered in both indications [7, 
9]. PK analyses also showed that the new dosing regi-
men of 840 mg every 3 weeks (q3w) resulted in higher 
pertuzumab concentrations and increased the probability 
of patients achieving a target serum trough concentration 
(Cmin) of pertuzumab similar to those observed in HER2-
positive EBC and MBC with the previously established 
840 mg loading dose followed by 420 mg q3w approved 
in those indications, without compromising the overall 
safety profile of the regimen [7]. The pertuzumab serum 
concentration of > 20 μg/mL was established as the target 
efficacious exposure (Cmin) based on non-clinical efficacy 
models [10].
JACOB (NCT01774786) was a prospective, randomized, 
multicenter, multinational, double-blind, placebo-controlled, 
phase III trial that evaluated the efficacy and safety of the 
new pertuzumab dosing regimen of 840 mg q3w adminis-
tered intravenously (IV) plus trastuzumab and chemotherapy 
(pertuzumab arm), compared with placebo plus trastuzumab 
and chemotherapy (placebo arm) as first-line therapy in 
patients with previously untreated HER2-positive metastatic 
GC or gastroesophageal junction cancer (MGC/GEJC) [11]. 
The JACOB study did not meet its primary endpoint of a 
statistically significant improvement in overall survival [OS; 
hazard ratio 0.84, 95% confidence interval (CI) 0.71–1.00, 
stratified log-rank p = 0.0565].
Here, we present data from the PK analysis of pertu-
zumab and trastuzumab in patients with MGC/GEJC in the 
JACOB study. A secondary objective of the JACOB study 
was to assess the pharmacokinetics of pertuzumab. Explora-
tory objectives included an assessment of PK drug–drug 
interactions (DDIs), pharmacokinetics of trastuzumab, the 
impact of anti-drug antibodies (ADAs) on PK, efficacy, and 
safety, effect of shed HER2 extracellular domain (ECD) on 
PK, and evaluation of the exposure–efficacy relationship, 




JACOB was a randomized, multicenter, multinational, 
double-blind, placebo-controlled, phase III trial evaluating 
the efficacy and safety of pertuzumab vs. placebo in com-
bination with trastuzumab and chemotherapy. The JACOB 
study design has been described previously [11]. In brief, 
patients aged ≥ 18 years with HER2-positive MGC/GEJC, 
measurable or evaluable non-measurable disease at base-
line, Eastern Cooperative Oncology Group performance 
status of 0 or 1, and baseline left ventricular ejection frac-
tion ≥ 55% were eligible; patients who had received the 
previous therapy with an HER2-targeted drug or previ-
ous systemic chemotherapy for metastatic disease were 
excluded.
Enrolled patients were randomized 1:1 to receive per-
tuzumab or placebo (840 mg pertuzumab or placebo given 
IV q3w) plus trastuzumab (IV; 8 mg/kg loading dose fol-
lowed by 6 mg/kg maintenance dose, q3w) and chemo-
therapy (oral capecitabine: 1000 mg/m2, taken twice daily 
on days 1–15, q3w, or 5-fluorouracil: 800 mg/m2/24 h IV 
by continuous infusion for 120 h on days 1–5, q3w; plus 
cisplatin: 80 mg/m2 IV on day 1 only, q3w). Randomiza-
tion was stratified by geographic region (Japan vs. North 
America/Western Europe/Australia vs. Asia [excluding 
Japan] vs. South America/Eastern Europe), prior gastrec-
tomy, and HER2 immunohistochemistry. Pertuzumab (or 
placebo) and trastuzumab were given until disease pro-
gression or unacceptable toxicity. Chemotherapy was 
given for six treatment cycles and only discontinued dur-
ing or before Cycle 6 for progressive disease or unaccep-
table toxicity.
The JACOB study was conducted in accordance with 
the International Conference on Harmonisation E6 guide-
line for Good Clinical Practice (ICH–GCP E6) and the 
principles of the Declaration of Helsinki, or the laws 
and regulations of the country in which the research was 
done; whichever provided the greater protection for the 
individual.
PK, anti‑drug antibodies, and HER2 extracellular 
domain sampling
PK samples were taken from all patients in the JACOB 
study for the PK analysis of pertuzumab and trastuzumab. 
Serum samples were collected pre-dose at Cycles 1, 2, 3, 4, 
6, and 8 and post-infusion at Cycles 1, 2, 4, and 8. Cycle 8 
serum samples were collected when patients were on bio-
logic therapy (i.e., pertuzumab and/or trastuzumab) alone 
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and the last chemotherapy administration was ≥ 6 weeks 
ago. Two additional serum samples were collected at 
post-treatment monitoring visits at 28 (± 7) days and 
60‒90 days after last study treatment administration (post-
treatment monitoring visits 1 and 2, respectively) to sup-
port interpretation of anti-drug antibody (ADA) with mini-
mized potential for drug interference in the ADA assay. 
These samples were analyzed for pertuzumab (pertuzumab 
arm only) and trastuzumab (pertuzumab and placebo arms) 
concentrations by  PPD® Laboratories, LLC (Richmond, 
VA, USA) using validated assays.
Based on historical data in EBC and MBC, pertuzumab 
steady state should be reached at day 43, following one load-
ing and one maintenance dose [1, 10]. Pertuzumab PK char-
acterization in this study was performed using observed data 
only, not model predicted, which could account for time-
dependent clearance. Therefore, the latest cycle of observed 
data, where most patients remained on study (Cycle 5), was 
used to designate steady state.
Prior pertuzumab population PK (popPK) analyses did 
not indicate that geographic region or race were covariates 
on clearance or volume; however, geographic region was 
one of the stratification factors of the JACOB study, as dif-
ferent regions have different screening and early detection 
practices, which could influence efficacy. Therefore, ensur-
ing no pertuzumab exposure differences in this large global 
trial was warranted.
Serum samples to test for the presence of ADAs against 
pertuzumab were collected from all patients pre-dose at 
Cycles 1, 3, and 6 and at post-treatment monitoring visits 1 
and 2. The samples were analyzed for ADAs against pertu-
zumab (pertuzumab arm only) by  PPD® Laboratories, LLC 
using a validated immunoassay.
Separate blood samples were obtained for the assessment 
of serum concentration of shed HER2 extracellular domain 
(ECD) at pre-dose at Cycles 1, 3, and 6, and during post-
treatment monitoring visit 1. The samples were analyzed for 
shed HER2 ECD by Covance Laboratories (Indianapolis, IN, 
USA) using a validated immunoassay.
Bioanalytical methods
Serum concentrations of pertuzumab were determined by 
a validated enzyme-linked immunosorbent assay (ELISA) 
with a minimum quantifiable concentration of 150 ng/mL 
[12]. The ELISA assay showed acceptable accuracy (% 
difference) and inter-assay percent coefficient of variation 
(% CV) with ranges of − 8.75 to 3.84% and 3.89–15.3%, 
respectively.
Serum concentrations of trastuzumab were determined by 
a validated high-performance liquid chromatography assay 
with tandem mass spectrometry detection (minimum quanti-
fiable concentration of 100 ng/mL) [13]. This assay showed 
acceptable accuracy (% difference) and % CV with ranges 
of − 8.08 to − 1.47% and 3.07 to 8.44%, respectively.
A validated ELISA was used to detect and confirm the 
presence of ADAs to pertuzumab in human serum. This 
assay used two conjugated reagents to capture ADAs 
directed against pertuzumab: biotin-conjugated pertuzumab 
and digoxin-conjugated pertuzumab. Bound ADAs to per-
tuzumab were then detected with a mouse anti-digoxin 
antibody conjugated with horseradish peroxidase. Using an 
anti-idiotypic mAb directed against pertuzumab as a posi-
tive control, the relative sensitivity was determined to be 
3.59 ng/mL in the absence of pertuzumab. In the presence 
of 200 μg/mL pertuzumab, the assay can detect 500 ng/mL 
of the anti-idiotypic mAb control.
Serum concentrations of HER2 ECD were measured 
using the commercially available ADVIA  Centaur® Serum 
HER-2/neu Assay (Siemens Healthcare Diagnostics Inc., 
Deerfield, IL, USA), a fully automated two-site sandwich 
immunoassay using direct chemiluminescent technology. 
The immunoassay has a minimum detectable concentra-
tion of 0.5 ng/mL; the assay showed acceptable accuracy 
(% recovery) and % CV with ranges of 88.7–100.9 and 
3.2–5.7%, respectively.
Data handling
All patients treated who had at least one documented per-
tuzumab or trastuzumab administration and at least one 
corresponding measurable concentration of pertuzumab or 
trastuzumab were included in the PK analysis, unless there 
were major protocol deviations or information that may have 
interfered with PK evaluation (i.e., labeling error, technical 
failure in sample analysis). Records were excluded if the 
time of drug administration or sample collection was miss-
ing. No imputation of PK values was performed. Observa-
tions with missing PK or time values, or those below the 
lower limit of quantification, were omitted from the analysis.
PK assessments
Peak (maximum) serum concentrations Cmax (post-dose) 
and Cmin (pre-dose) from prespecified collection timepoints 
were summarized using descriptive statistics and graphical 
assessment. Cmin refers to the concentration at the end of 
a dosing interval, and therefore, the pre-dose PK sample 
of a given cycle refers to the previous cycle’s Cmin (i.e., 
pre-dose Cycle 6 is the Cycle 5 Cmin). To reduce burden 
for patients and healthcare providers, sparse PK sampling 
was used, where only pre-dose and a few post-dose samples 
were collected. Steady-state concentrations of pertuzumab 
(Cmax,ss and Cmin,ss) from JACOB were compared across dif-
ferent geographic regions (a prespecified stratification fac-
tor in the study): Japan, North America/Western Europe/
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Australia, Asia (excluding Japan), and South America/
Eastern Europe. Steady-state concentrations of pertuzumab 
from JACOB were compared with equivalent data obtained 
in the previous studies of women with MBC (CLEOPATRA, 
NCT00567190) [9] and patients with AGC (JOSHUA) [7]. 
Similarly, steady-state concentrations of trastuzumab from 
JACOB were compared with equivalent data obtained in the 
previous AGC studies (JOSHUA and ToGA) [7, 14].
Analysis of DDIs
Potential effects of pertuzumab on the steady-state PK of 
trastuzumab were assessed by comparing the arithmetic 
means of serum trastuzumab concentrations at pre-dose 
Cycle 6 (Cycle 5 Cmin,ss) and post-dose (Cmax,ss) in Cycle 
4 between the pertuzumab and placebo arms. In addition, 
the 90% CI for the ratio of the geometric means were con-
structed. Potential effects of chemotherapy on pertuzumab or 
trastuzumab PK were assessed by comparing the arithmetic 
means of Cmin in Cycle 5 (with chemotherapy) and Cycle 7 
(without chemotherapy). If the 90% CI of the ratio of arith-
metic means was contained within 80–125%, no apparent 
DDI was concluded.
Exploratory exposure–efficacy analyses
Observed individual pertuzumab exposures at Cycle 1 and at 
steady state from patients in the pertuzumab arm were used 
in the exploratory exposure–efficacy analysis. The efficacy 
endpoint in the analysis was the primary study endpoint, 
OS. Patients who had not had an event at the time of data 
analysis were censored at the date they were last known to 
be event free. The primary exposure metrics used in the 
exposure–efficacy analysis were individual-observed Cycle 
1 Cmin and Cycle 5 Cmin,ss. Individuals who died prior to 
Cycle 6 were not included in the analysis. Kaplan–Meier 
curves were generated to determine survival probability 
within Cycle 1 and Cycle 5 Cmin quartiles. A log-rank test 
determined whether statistically significant survival differ-
ences existed among Cmin quartiles.
Assessment of ADAs on PK, safety, and efficacy
Incidence of ADAs to pertuzumab was measured and the 
impact of ADAs on pertuzumab PK, safety, and efficacy was 
assessed.
Assessment of HER2 ECD concentrations
Serum concentrations of HER2 ECD were measured in both 
treatment arms at baseline. The effect of shed HER2 ECD 
on pertuzumab PK was assessed.
Results
Study population and demographics
In JACOB, 780 patients were randomized to receive per-
tuzumab plus trastuzumab and chemotherapy (n = 388) or 
placebo plus trastuzumab and chemotherapy (n = 392). Of 
these, 374 patients in the pertuzumab arm and 375 patients 
in the placebo arm had evaluable PK data and were included 
in this analysis. Patient demographics and disease charac-
teristics at baseline in the intention-to-treat population are 
provided in Online Resource 1 [11].
PK analyses
Summary statistics of pertuzumab PK in patients treated 
with pertuzumab are presented in Table 1. Following the 
first IV administration of pertuzumab 840 mg, the mean 
observed Cmax ± standard deviation (SD) for pertuzumab 
was 258 ± 90.3 μg/mL. The mean observed Cmin,ss ± SD of 
Table 1  Summary of pharmacokinetic parameters


















 n 374 349 305 302 274 114 106
 Mean (SD) 258 (90.3) 42.4 (24.8) 90.4 (42.4) 341(111) 114 (51.8) 142 (67.9) 371 (127)
Trastuzumab (pertuzumab arm)
 n 372 345 305 304 274 114 115
 Mean (SD) 142 (86.8) 15.4 (11.3) 22.9 (12.7) 127 (50.9) 26.3 (14.8) 32.7 (15.0) 130 (50.8)
Trastuzumab (placebo arm)
 n 375 354 300 299 254 92 90
 Mean (SD) 139 (58.6) 17.2 (15.4) 24.1 (19.0) 129 (58.1) 29.8 (21.9) 37.4 (20.3) 147 (90.2)
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Fig. 1  Cross-study comparison of PK for a pertuzumab [7, 9, 11] and 
b trastuzumab [7, 11, 14]. Cmax,ss steady-state peak (maximum) serum 
concentration, Cmin,ss steady-state serum trough (minimum) concen-
tration, PK pharmacokinetic. Cycle numbers for Cmin,ss and Cmax,ss 
vary between studies. Cmin,ss: JACOB, Cycle 3 pre-dose; JOSHUA, 
Cycle 4 pre-dose; CLEOPATRA, Cycle 9 pre-dose; ToGA, Cycle 
9 pre-dose. Cmax,ss: JACOB, Cycle 4 post-dose; JOSHUA, Cycle 4 
post-dose; CLEOPATRA, Cycle 9 post-dose; ToGA, Cycle 5 post-
dose. Red bars = Cmin; blue bars = Cmax; lower and upper ends of 
each box plot = 25th and 75th percentile exposure value; horizontal 
white line = median per group; points = individual PK data. Brackets 
extending from the ends of the box are drawn to the nearest value, not 
beyond 1.5 times the interquartile range
544 Cancer Chemotherapy and Pharmacology (2019) 84:539–550
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pertuzumab following five subsequent pertuzumab doses at 
840 mg q3w at Cycle 5 was 114 ± 51.8 μg/mL (Table 1). 
The target Cmin,ss of ≥ 20 μg/mL was reached in 99.3% of 
patients at Cycle 5 Cmin,ss and beyond. In addition, > 90% of 
patients were above the PK target right after the first pertu-
zumab dose.
Summary statistics of trastuzumab PK in patients treated 
with trastuzumab (pertuzumab and placebo arms) are pre-
sented in Table 1. Following the loading dose IV admin-
istration of trastuzumab at 8 mg/kg, the mean observed 
Cmax ± SD of trastuzumab was 142 ± 86.8 μg/mL in the 
pertuzumab arm and 139 ± 58.6 μg/mL in the placebo arm 
(Table 1). The mean observed Cmin,ss of trastuzumab follow-
ing five subsequent trastuzumab maintenance doses of 6 mg/
kg q3w in Cycle 5 was 26.3 ± 14.8 μg/mL in the pertuzumab 
arm and 29.8 ± 21.9 μg/mL in the placebo arm (Table 1).
Comparison of pertuzumab and trastuzumab PK 
data from JACOB with the previous studies in MBC 
and AGC, and across geographic regions
Pertuzumab Cmin,ss from JACOB was comparable to the pre-
vious studies in MBC (CLEOPATRA; 840 mg loading dose 
followed by 420 mg maintenance dose q3w) [9] and AGC 
(JOSHUA; 840 mg q3w arm) [7] (Fig. 1a). The higher pertu-
zumab dose in the JACOB study was reflected in higher Cmax 
concentrations at steady state, compared with CLEOPATRA 
(mean Cmax ± SD: 341 ± 111 vs. 196 ± 66.3) and consist-
ent with Cmax in JOSHUA (mean Cmax ± SD [840 mg q3w 
arm]: 316 ± 134 μg/mL). Steady-state trastuzumab PK from 
JACOB was comparable to the previous studies in AGC 
(JOSHUA [840 mg q3w arm] [7] and ToGA [14]) (Fig. 1b).
Cmin,ss for pertuzumab across the different geographic 
regions are shown in Online Resource 2. Pertuzumab expo-
sure was comparable across geographic regions.
DDIs
The ratio of arithmetic means of Cmin,ss serum trastuzumab 
concentrations at Cycle 5 (pre-dose Cycle 6) in the pertu-
zumab versus placebo arm was 90.9% (90% CI 81.5–101.5). 
The ratio of arithmetic means of Cmax,ss serum trastuzumab 
concentrations at Cycle 4 in the pertuzumab versus placebo 
arm was 101.5% (90% CI 94.8–108.8). Trastuzumab PK 
parameters were comparable between the pertuzumab and 
placebo arms, suggesting that adding pertuzumab-to-trastu-
zumab treatment did not alter the PK of trastuzumab (Fig. 2).
For patients in the pertuzumab arm who completed the 
last chemotherapy treatment in Cycle 6 and continued per-
tuzumab 840 mg treatment without chemotherapy thereafter, 
the Cycle 7 observed that mean Cmin of pertuzumab was 
142 ± 67.9 μg/mL. This was comparable to the pertuzumab 
PK exposure in Cycle 5 when patients were treated with per-
tuzumab in combination with trastuzumab and chemother-
apy (Fig. 2a), indicating that chemotherapy had no apparent 
impact on pertuzumab PK.
For patients who completed the last chemotherapy treat-
ment in Cycle 6 and continued 6 mg/kg trastuzumab without 
chemotherapy thereafter, the Cycle 7 observed mean Cmin 
of trastuzumab was 32.7 ± 15.0 μg/mL in the pertuzumab 
arm and 37.4 ± 20.3 μg/mL in the placebo arm, which was 
comparable to the PK exposure in Cycle 5 when patients 
were treated with pertuzumab or placebo in combination 
with trastuzumab and chemotherapy (Fig. 2b), suggesting 
that chemotherapy had no impact on trastuzumab PK.
Exposure–efficacy relationships
There were no statistically significant differences in OS 
across Cycle 1 pertuzumab Cmin or Cycle 5 pertuzumab 
Cmin,ss quartiles (Fig. 3). The median OS in weeks for Cycle 
1 pertuzumab Cmin quartiles were Q1: 43, Q2: 23, Q3: 28, 
and Q4: 40 (n = 349, p = 0.52) and the median OS in weeks 
for Cycle 5 pertuzumab Cmin,ss quartiles were Q1: 26, Q2: 
28, Q3: 26, and Q4: 38 (n = 274, p = 0.78).
Immunogenicity
At baseline, 746 patients were evaluable for ADAs (pertu-
zumab arm, n = 376; placebo arm, n = 370); 21 patients in 
the pertuzumab arm and 14 patients in the placebo arm were 
ADA-positive at baseline (likely reflecting false positives or 
pre-existing ADAs). Of the 347 ADA-evaluable patients in 
the pertuzumab arm who had at least one post-dose sample 
available, only two were ADA-positive (0.6%). The pertu-
zumab Cmin,ss for the two ADA-positive patients—135 ug/
mL and 59.8 ug/mL, respectively—are within the range 
observed in the studied population.
Effect of baseline shed HER2 ECD on pertuzumab PK
There was considerable inter-patient variability in base-
line HER2 ECD concentrations, as reflected by the broad 
ranges of individual values (3.5–2086.4 ng/mL) observed 
in both treatment arms of the study; however, most patients 
had baseline HER2 ECD concentrations below 100 ng/
Fig. 2  Drug–drug interaction assessment of the potential effects 
of a chemotherapy on pertuzumab exposure and b pertuzumab on 
trastuzumab exposure. C Cycle, Chemo chemotherapy, Cmax peak 
(maximum) serum concentration, Cmin serum trough (minimum) 
concentration, PK pharmacokinetic. Red bars = post-dose; blue 
bars = pre-dose; lower and upper ends of each box plot = 25th and 
75th percentile exposure value; horizontal white line = median per 
group; points = individual PK data. Brackets extending from the ends 
of the box are drawn to the nearest value, not beyond 1.5-times the 
interquartile range
◂
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mL. In the pertuzumab arm, the mean ± SD and min–max 
baseline ECD concentrations were 42.1 ± 119 ng/mL and 
3.5–1350 ng/mL, respectively (n = 361). Similar results were 
observed in the placebo treatment arm. No apparent rela-
tionship was seen between pertuzumab Cmin,ss and baseline 
HER2 ECD concentrations (Fig. 4). HER2 ECD concentra-
tions observed in JACOB were comparable to concentrations 
observed previously in breast cancer (F. Hoffmann-La Roche 
Ltd. Data on file).
Discussion
The JACOB trial did not meet its primary endpoint of 
showing a statistically significant improvement in OS in 
patients who received pertuzumab in addition to trastu-
zumab and chemotherapy, compared to those who did 
not receive pertuzumab. However, there was utility in 
conducting a PK analysis to better understand the pertu-
zumab PK–pharmacodynamic relationship and to assess 
the appropriateness of the new pertuzumab dosing regimen 
selected for this indication. Collection of serum samples 
from all patients who participated in the JACOB study 
enabled this extensive characterization of the PK of pertu-
zumab in patients with HER2-positive MGC/GEJC.
The appropriateness of an 840  mg q3w dose was 
assessed in an exposure–efficacy analysis, which showed 
no statistically significant relationship between pertu-
zumab exposure quartiles and the probability of survival. 
Our findings, therefore, provide no evidence of additional 
efficacy with increasing pertuzumab exposure in this 
trial. Given the overall JACOB study outcome, which 
showed that OS was not significantly different between 
treatment and control (median OS 17.5 months [95% CI 
Fig. 3  Kaplan–Meier plot of overall survival by pertuzumab exposure quartiles at a Cycle 1 (Cmin) and b Cycle 5 (Cmin,ss)
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16.2–19.3] in the pertuzumab arm and 14.2 months [95% 
CI 12.9–15.5] in the control arm; hazard ratio 0.84 [95% 
CI 0.71–1.00]; p = 0.57), the power to detect a difference 
between exposure quartiles in the treatment arm would be 
predictably very small.
In JACOB, 99.3% of patients with HER2-positive 
MGC/GEJC achieved target Cmin,ss, the target efficacious 
exposure based on the previous non-clinical efficacy mod-
els [10] when receiving the 840 mg q3w pertuzumab dose. 
In comparison, pertuzumab PK data from the registrational 
phase II NeoSphere study (pertuzumab, trastuzumab, 
and docetaxel in the neoadjuvant treatment of HER2-
positive EBC; NCT00545688) showed that the 840 mg 
loading dose followed by 420 mg q3w pertuzumab regi-
men resulted in 94% of patients reaching the target Cmin,ss 
of > 20 μg/mL [10]. The exposure–response analysis 
from NeoSphere also showed that there was no significant 
impact (p = 0.996) on the probability of the primary study 
endpoint (pathologic complete response in the breast) with 
an increase in pertuzumab serum concentration beyond 20 
μg/mL [10]. The findings of this exposure–response analy-
sis were also replicated in the phase III APHINITY study 
(pertuzumab, trastuzumab, and chemotherapy for the adju-
vant treatment of HER2-positive EBC; NCT01358877) 
[15]. These two studies in patients with breast cancer 
support the selection of ≥ 20 µg/mL as a rational target 
serum trough exposure level of pertuzumab for therapeutic 
efficacy. Therefore, the 840 mg q3w dose, which enabled 
target pertuzumab concentrations to be achieved in the vast 
majority of patients with HER2-positive MGC/GEJC in 
the JACOB study, appears to be an appropriate selection 
from a PK/pharmacodynamic perspective. Furthermore, 
efficacious exposures of trastuzumab were also obtained 
in JACOB, as evidenced by a consistent  % of patients 
reaching the target trastuzumab Cmin as in the pivotal trial 
ToGA [14]. In addition, in JACOB, trastuzumab Cmin at 
Cycles 1 and 5 were similar in both the pertuzumab and 
placebo treatment arms.
Pertuzumab was well tolerated in the JACOB study and 
the safety profile was generally similar between the two 
treatment groups [11]. No new or unexpected safety events 
were reported, which is important given that the dose of 
840 mg pertuzumab every 3 weeks was double the main-
tenance dose currently approved for breast cancer treat-
ment [11]. Given the lack of significant improvements in 
efficacy outcomes and that pertuzumab was well tolerated 
at a higher dose, decreasing the pertuzumab dose was not 
justified as a viable treatment option, and therefore, no 
exposure–safety analyses were warranted.
No DDIs were found in this study, which is as expected 
based on prior data on pertuzumab and trastuzumab PK 
[10, 12] and the distinct clearance mechanisms between 
mAbs and small-molecule chemotherapy agents [16–18]. 
Pertuzumab and trastuzumab bind to distinct epitopes of 
HER2 simultaneously without steric hinderance, providing 
an additional rationale for why no DDI was expected [19].
There was no apparent impact of ADAs on pertuzumab 
PK in patients who were ADA-positive, and no apparent 
impact on safety as neither ADA-positive patient had any 
serious immune-related AEs nor other AEs suggestive of 
hypersensitivity. Although data were limited, there was 
no apparent impact on efficacy, as both patients were 
identified as partial responders (OS: 39 and 15 months; 
progression-free survival: 14 and 11 months). The ADA 
results from the JACOB study confirm the low immuno-
genic potential of pertuzumab, as reported in other indica-
tions [1].
Pertuzumab exposure in JACOB was consistent with 
prior studies in AGC (the phase  IIa dose-finding study, 
JOSHUA, which used 840 mg q3w) and breast cancer (e.g., 
Fig. 4  Pertuzumab steady-state 
exposure vs. HER2 ECD con-
centrations. Cmin serum trough 
(minimum) concentration, ECD 
extracellular domain, HER2 
human epidermal growth factor 
receptor 2
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CLEOPATRA, which used 840 mg loading dose followed 
by 420 mg q3w). This further supports the existence of a 
significant difference in the clearance of pertuzumab based 
on indication. The difference in pertuzumab PK in AGC 
vs. MBC indications identified in JOSHUA led to the deci-
sion to pursue an 840 mg q3w dosing regimen in JACOB 
rather than the 840 mg/420 mg q3w regimen approved in the 
HER2-positive breast cancer indication [1, 2]. The observed 
difference in clearance in AGC compared with other indi-
cations is consistent with other mAbs and antibody–drug 
conjugates such as trastuzumab, bevacizumab, and ado-
trastuzumab emtansine [20].
It should be noted that exposures in JACOB were limited 
to Cmax and Cmin only, due to the sparse PK sampling sched-
ule employed in this large Phase III clinical trial. Within 
cycle pertuzumab, PK samples collected in the previous 
gastric cancer study (JOSHUA), pooled with the sparse PK 
samples collected in the JACOB study, were deemed suffi-
cient to characterize pertuzumab PK in this patient popula-
tion. Here, we rely on Cmax and Cmin only when comparing 
across geographies or to prior studies such as JOSHUA, 
ToGA, and CLEOPATRA. This comparison gives a reason-
able idea of exposure similarities or differences. Without 
extensive sampling and the fact that post-dose and pre-dose 
PK samples were not collected during the same cycles in 
JACOB, the onset of steady state was concluded to be Cycle 
4 for Cmax,ss and Cycle 5 for Cmin,ss.
A popPK model of trastuzumab showed that no single 
covariate could explain the PK difference between AGC and 
MBC [21]. Hypotheses to explain possible reasons for faster 
clearance of HER2-targeting molecules in AGC include both 
target- and non-target-related mechanisms. HER2-target 
mechanisms include tumor burden and HER2 shed ECD. 
Tumor burden was ruled out as a potential mechanism in 
previously published popPK analyses [14]. Shed HER2 ECD 
was investigated within the JACOB study, as it was a signifi-
cant covariate for the clearance of trastuzumab or ado-tras-
tuzumab emtansine in MBC, although in these studies, the 
magnitude of impact was relatively small and not of clinical 
relevance [22, 23]. In the JACOB study, baseline shed HER2 
ECD levels were comparable to levels seen previously in 
breast cancer patients [F. Hoffmann-La Roche Ltd. Data on 
file] and there was no apparent relationship between baseline 
shed HER2 ECD and steady-state pertuzumab Cmin.
One promising non-target hypothesis is potential gas-
tric protein leakage or protein-losing enteropathy (PLE) in 
patients with AGC. There is no direct clinical evidence for 
a relationship between PLE and the PK of mAbs; however, 
it is conceivable that PLE could be a driving factor in faster 
mAb clearance, given that GC is one of the disease states asso-
ciated with PLE [24] and patients with PLE often develop 
hypoalbuminemia [25], which is known to be negatively cor-
related with mAb clearance [9, 14, 21, 23]. Yang et al. [26] 
showed a decrease in murine IgG1 mAb area under the curve 
for 0–14 days from 1368 ± 255 to 594 ± 224 μg/mL/day in a 
murine model of colitis and PLE, providing preclinical support 
of this potential hypothesis.
Further studies are needed to identify first-line treatment 
options to improve patient outcomes in HER2-positive AGC 
and to better identify patients who might benefit from dual 
anti-HER2 targeted regimens [11]. Using methods beyond 
the current process for identifying HER2-positive AGC may 
compensate for the intratumoral heterogeneity observed in 
GC, which may have negatively impacted responses to tar-
geted therapies in this and other trials [27, 28]. Furthermore, 
a comprehensive cross-antibody covariate analysis, as well 
as potential in vitro experiments and/or clinical studies, are 
warranted to further understand the clearance difference and 
to support appropriate dosing regimens of other biologics in 
this indication.
Acknowledgements We would like to acknowledge all volunteers, 
patients, and investigators participating in this study. This study is 
sponsored by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Sup-
port for third-party writing assistance for this manuscript, furnished 
by Rachel Johnson, PhD, of Health Interactions, was provided by F. 
Hoffmann-La Roche Ltd.
Funding This study is funded by F. Hoffmann-La Roche Ltd, Basel, 
Switzerland.
Compliance with ethical standards 
Conflict of interest All authors received support for third-party writing 
assistance for this manuscript, provided by F. Hoffmann-La Roche Ltd. 
Whitney Kirschbrown, Ihsan Nijem, Amit Garg, and Sandhya Girish 
are employees of Genentech, Inc., and hold stock in Roche Holding 
Ltd. Whitney Kirschbrown is an inventor on a pertuzumab-related fil-
ing. Bei Wang is an employee of Genentech, Inc. Atsushi Ohtsu has 
received research grants from BMS and honoraria from BMS, Ono, 
Chugai, and Taiho. Paulo M. Hoff has received research grants from 
Roche relating to the conduct of this study. Manish A. Shah disclos-
es research funding paid to his institution from Boston Biomedical, 
Merck, and Roche. Lin Shen received non-financial support from 
Roche Pharmaceuticals Ltd. relating to the conduct of this study and 
a research grant from Hengrui Medicine Co. Ltd, indirectly related to 
this manuscript. Yoon-Koo Kang has received research grants from 
Roche, Daehwa and LSK Biopharma, and has received personal fees 
from Ono, BMS, Novartis, Lilly, Daehwa, and LSK Biopharma. Maria 
Alsina has performed an advisory role for BMS, Servier, and MSD, 
received research funding from Merck-Serono, and received speaker 
fees from MSD, BMS, Lilly, Roche, Amgen, and AstraZeneca.
Ethical standards The study was conducted in accordance with the 
ethical standards established in the 1964 Declaration of Helsinki and its 
later amendments. The study was approved by the institutional review 
board of each study site, and all patients participating in the study 
provided informed consent before enrollment.
549Cancer Chemotherapy and Pharmacology (2019) 84:539–550 
1 3
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Genentech Inc (2018) Perjeta™ (pertuzumab). Prescribing Infor-
mation (USA). https ://www.acces sdata .fda.gov/drugs atfda _docs/
label /2018/12540 9s121 lbl.pdf. Accessed 18 Dec 2018
 2. Roche Registration Ltd (2018)  Perjeta® (pertuzumab). Summary 
of Product Characteristics. https ://www.ema.europ a.eu/docum 
ents/produ ct-infor matio n/perje ta-epar-produ ct-infor matio n_en-0.
pdf. Accessed 18 Dec 2018
 3. Harbeck N, Beckmann MW, Rody A et al (2013) HER2 dimeriza-
tion inhibitor pertuzumab—mode of action and clinical data in 
breast cancer. Breast Care (Basel) 8:49–55
 4. Baselga J, Cortés J, Kim SB et al (2012) Pertuzumab plus trastu-
zumab plus docetaxel for metastatic breast cancer. N Engl J Med 
366:109–119
 5. Swain SM, Baselga J, Kim SB et al (2015) Pertuzumab, trastu-
zumab, and docetaxel in HER2-positive metastatic breast cancer. 
N Engl J Med 372:724–734
 6. von Minckwitz G, Procter M, de Azambuja E et al (2017) Adju-
vant pertuzumab and trastuzumab in early HER2-positive breast 
cancer. N Engl J Med 377:122–131
 7. Kang YK, Rha SY, Tassone P et al (2014) A phase IIa dose-find-
ing and safety study of first-line pertuzumab in combination with 
trastuzumab, capecitabine and cisplatin in patients with HER2-
positive advanced gastric cancer. Br J Cancer 111:660–666
 8. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab 
in combination with chemotherapy versus chemotherapy alone for 
treatment of HER2-positive advanced gastric or gastro-oesopha-
geal junction cancer (ToGA): a phase 3, open-label, randomised 
controlled trial. Lancet 376:687–697
 9. Garg A, Quartino A, Li J et al (2014) Population pharmacokinetic 
and covariate analysis of pertuzumab, a HER2-targeted monoclo-
nal antibody, and evaluation of a fixed, non-weight-based dose in 
patients with a variety of solid tumors. Cancer Chemother Phar-
macol 74:819–829
 10. Quartino AL, Li H, Jin JY et al (2017) Pharmacokinetic and 
exposure–response analyses of pertuzumab in combination with 
trastuzumab and docetaxel during neoadjuvant treatment of HER2 
early breast cancer. Cancer Chemother Pharmacol 79:353–361
 11. Tabernero J, Hoff PM, Shen L et al (2018) Pertuzumab plus tras-
tuzumab and chemotherapy for HER2-positive metastatic gastric 
or gastro-oesophageal junction cancer (JACOB): final analysis 
of a double-blind, randomised, placebo-controlled phase 3 study. 
Lancet Oncol 19:1372–1384
 12. Cortés J, Swain SM, Kudaba I et al (2013) Absence of pharma-
cokinetic drug-drug interaction of pertuzumab with trastuzumab 
and docetaxel. Anticancer Drugs 24:1084–1092
 13. Liu L, Xu K, Li J et al (2018) Optimizing hybrid LC-MS/MS 
binding conditions is critical: impact of biotransformation on 
quantification of trastuzumab. Bioanalysis 10(22):1819–1831
 14. Cosson VF, Ng VW, Lehle M, Lum BL (2014) Population phar-
macokinetics and exposure–response analyses of trastuzumab in 
patients with advanced gastric or gastroesophageal junction can-
cer. Cancer Chemother Pharmacol 73:737–747
 15. Kirschbrown WP, Kagedal M, Wang B et al (2018) Pharmacoki-
netic and exploratory exposure-response analysis of pertuzumab 
in patients with operable HER2-positive early breast cancer. Clin 
Pharmacol Ther 103(Suppl):S74
 16. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH (2010) Clini-
cal pharmacokinetics of therapeutic monoclonal antibodies. Clin 
Pharmacokinet 49:493–507
 17. Sonnichsen DS, Relling MV (1994) Clinical pharmacokinetics of 
paclitaxel. Clin Pharmacokinet 27:256–269
 18. van der Vijgh Wim JF (1991) Clinical pharmacokinetics of car-
boplatin. Clin Pharmacokinet 21:242–261
 19. Lu D, Burris HA 3rd, Wang B et al (2012) Drug interaction 
potential of trastuzumab emtansine (T-DM1) combined with per-
tuzumab in patients with HER2-positive metastatic breast cancer. 
Curr Drug Metab 13:911–922
 20. Chen SC, Kagedal M, Gao Y et al (2017) Population pharmacoki-
netics of trastuzumab emtansine in previously treated patients with 
HER2-positive advanced gastric cancer (AGC). Cancer Chem-
other Pharmacol 80:1147–1159
 21. Han K, Jin J, Maia M, Lowe J, Sersch MA, Allison DE (2014) 
Lower exposure and faster clearance of bevacizumab in gastric 
cancer and the impact of patient variables: analysis of individual 
data from AVAGAST phase III trial. AAPS J 16:1056–1063
 22. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein 
P (2005) Population pharmacokinetics of trastuzumab in patients 
with HER2 + metastatic breast cancer. Cancer Chemother Phar-
macol 56:361–369
 23. Lu D, Girish S, Gao Y et al (2014) Population pharmacokinetics 
of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-
drug conjugate, in patients with HER2-positive metastatic breast 
cancer: clinical implications of the effect of covariates. Cancer 
Chemother Pharmacol 74:399–410
 24. Nakatani N (1994) Quantitative study of serum protein loss into 
the alimentary tract in patients with gastric cancer [article in Japa-
nese]. Nihon Shokakibyo Gakkai Zasshi 91:1391–1398
 25. Strygler B, Nicar MJ, Santangelo WC, Porter JL, Fordtran JS 
(1990) Alpha 1-antitrypsin excretion in stool in normal subjects 
and in patients with gastrointestinal disorders. Gastroenterology 
99:1380–1387
 26. Yang Y, Li TR, Balthasar JP (2017) Investigation of the influence 
of protein-losing enteropathy on monoclonal antibody pharma-
cokinetics in mice. AAPS J 19:1791–1803
 27. Alsina M, Gullo I, Carneiro F (2017) Intratumoral heterogeneity 
in gastric cancer: a new challenge to face. Ann Oncol 28:912–913
 28. Gullo I, Carneiro F, Oliveira C, Almeida GM (2018) Heterogene-
ity in gastric cancer: from pure morphology to molecular clas-
sifications. Pathobiology 85:50–63
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
550 Cancer Chemotherapy and Pharmacology (2019) 84:539–550
1 3
Affiliations
Whitney P. Kirschbrown1 · Bei Wang1 · Ihsan Nijem1 · Atsushi Ohtsu2 · Paulo M. Hoff3 · Manish A. Shah4 · Lin Shen5 · 
Yoon‑Koo Kang6 · Maria Alsina7 · Sandhya Girish1 · Amit Garg1 
1 Clinical Pharmacology, Genentech Research and Early 
Development, DNA Way, MS463a, South San Francisco, 
CA 94080, USA
2 Department of Gastrointestinal Oncology, National Cancer 
Center Hospital East, Kashiwa, Japan
3 Instituto do Câncer de São Paulo, Faculdade de Medicina da 
Universidade de São Paulo, São Paulo, Brazil
4 Medical Oncology/Solid Tumor Program, Sandra 
and Edward Meyer Cancer Center, Weill Cornell Medical 
College, New York, NY, USA
5 Key Laboratory of Carcinogenesis and Translational 
Research (Ministry of Education/Beijing), Department 
of Gastrointestinal Oncology, Peking University Cancer 
Hospital and Institute, Beijing, China
6 Department of Oncology, Asan Medical Center, University 
of Ulsan College of Medicine, Seoul, Korea
7 Vall d’Hebron University Hospital and Institute of Oncology 
(VHIO), Universitat Autònoma de Barcelona, Barcelona, 
Spain
